Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Xyphos

- PMLiVE

Bluebird’s myeloma CAR-T safety ‘could support outpatient use’

Expects to file with the FDA next year

- PMLiVE

Gracell Bio developing faster, cheaper CAR-T production

Manufacturing can be cut from two weeks to one day

- PMLiVE

Poseida gets Novartis backing for myleoma CAR-T challenger

San Diego firm joins crowded field

- PMLiVE

CHMP recommends new Keytruda dosing schedule

Will apply to eight indications across five tumour types

- PMLiVE

CMS proposes coverage scheme for CAR-T therapies

Proposal says it would improve access to CAR-Ts

- PMLiVE

AbbVie enters BCMA race with Teneobio deal

Agreement includes option to acquire TeneoOne

- PMLiVE

Trulicity’s ascent lifts Lilly

Diabetes treatment leads new product growth

Bristol Myers Squibb logo

BMS isn’t phased by Opdivo’s slowing growth – for now

Lung cancer filing withdrawn after FDA reservations

Eli Lilly HQ

Lilly adds to pharma M&A run with $8bn Loxo buy-out

Lilly claims company ahead of more dominant oncology players

Sanofi reception

Sanofi and Regeneron re-jig immuno-oncology deal

Partners refocus around two promising bispecific candidates

- PMLiVE

Novartis buys CellforCure to bolster cell, gene therapy

Move would make existing partner an in-house capability

- PMLiVE

Dragonfly signs Celgene as partner for NK cell platform

Extends presence in haemato-oncology and solid tumours

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links